Armin W. Mäder

Tougher times in startup financing - but there are also good news: biotech and early-stage investments are on the rise. Learn more in the latest update of the Swiss Venture Capital Report 2024, published by Startupticker.ch, SECA - Swiss Private Equity & Corporate Finance Association, and Startup.ch: https://lnkd.in/ek7uNCKk #SwissStartups #VentureCapital #Switzerland

13

Flexible, standardized, agnostic! Two years ago, we evaluated the best possible technology for making a difference in the Swiss healthcare system. Thus we chose Trifork’s health platform. Based on this and using Trifork’s extensive experience from digitizing the Danish healthcare system, we created the Compassana health platform and developed a range of relevant and value-adding tools for both patients and healthcare providers. This is how we are building a leading integrated patients/clinicians experience. Now, the possibilities are endless because the two biggest players use the same technology base. eHealth Suisse Die Schweizerische Post Helsana Versicherungen AG SWICA Medbase Gruppe Hirslanden Luzerner Kantonsspital Groupe Mutuel

62

Do you want to start an Early Access Program in Switzerland but you're unsure where to start or don't know what the regulations are? In our latest expert guide, we've listed the different routes to gain easier market access in Switzerland for products not yet authorized. Download our exclusive guide today and make sure your orphan drug reaches the patients who need it most. https://lnkd.in/eAAXgjmr #rarediseases #orphandrugs #marketaccess

14

BGPartner advises Novo Holdings, EQT, OrbiMed and SR One on $100 mio Series C financing of Asceneuron SA Swiss biotech company Asceneuron SA successfully closed a $100 mio oversubscribed Series C financing round. The financing round was led by Novo Holdings with new investment from EQT Life Sciences - LSP Dementia Fund, OrbiMed and SR One Capital Management, alongside participation from existing investors Merck Serono S.p.A., Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. The funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical development for the treatment of Alzheimer’s disease. BGPartner advised lead investor Novo Holdings as well as the investors EQT Life Sciences - LSP Dementia Fund, OrbiMed and SR One, on all Swiss legal matters and the negotiations of this Series C financing round. The team consisted of Oliver Gnehm (Partner), Victoria Marty (Senior Associate) and Tessa Douma (Associate). More information can be found here: https://lnkd.in/d278vevG More information about our legal and negotiation expertise can be found here: https://lnkd.in/eFQjD5fw #Financing #swiss #Biotech #law #negotiation #Alzheimer

34

Unfortunately, the latest report (https://lnkd.in/eriE95Tw) shows that Switzerland when compared internationally is losing commercial competitiveness and attractiveness to launch new innovative medicines; unfortunately and ultimately, the ones that are paying the price are patients. This hiccup is mainly caused by the Federal Office of Health (BAG). According to the Federal Office of Statistics about one third of the Swiss professionally active population is working part-time, while according to the BAG ‘s website their part-time working force is two-thirds. How can you run effectively a key national function that monitors and controls the Swiss health with an organization that has about two-thirds of the working force working part-time??? Maybe you could, with a top notch federal fully integrated health digital infrastructure, but here as well we are ages behind others… However, on a positive note, what we do have are happy wagging dogs in the offices of the BAG…. The health of a Nation is a natural resource and a strategic asset for the future, and as such should be prioritized!

11

1 Kommentar

🔬 Ever wondered how working at an Innovation Space may enhance your ability to collaborate and fast-forward your next groundbreaking innovation?   Basel-based Engimmune Therapeutics and the Swiss innovation center CSEM, housed at the Switzerland Innovation Park Basel Area - Main Campus HQ, discuss in an interview how and why they started to work together to advance cancer treatment. Watch it below 👇 Engimmune Therapeutics, also part of BaseLaunch's portfolio, is a spin-off from ETH Zürich on a quest to revolutionize cancer treatment with soluble T cell receptors (TCR). CSEM, a landmark of Swiss technological innovation, is on a mission to bridge the gap between research and industry. The synergy between Engimmune’s TCR technology and CSEM’s microfluidic prowess has set the stage for a leap in cancer therapy development. By encapsulating individual TCR tests in microscopic droplets, cross-contamination is eliminated, ensuring precise and reliable results. This innovation dramatically accelerates the screening process, turning what used to take months into a matter of weeks, and significantly increasing the number of TCR candidates that can be de-risked in preparation for clinical trials. Read the full article right here: https://lnkd.in/eiGCKE3Y Rodrigo Vazquez-Lombardi | Felix K. #innovation #startups #collaboration #healthcare #lifescience

43

How do groundbreaking ideas transition from the lab to the market? Our Venture Partner in the biotech team, Kathrin Ballesteros Katemann, recently shed light on this journey during her lecture in the "Beyond Papers: Research in Practice" series. In her session, "From Bench to Bedside: What to Consider in Drug Development," Kathrin explored the crucial steps in translating research into practical drug development. With over 20 years of experience supporting startups in the life sciences sector, Kathrin is a master at transforming early-stage scientific projects into valuable businesses. Beyond her scientific expertise, she is also a skilled Business Coach, Team Coach, and Team Developer. 𝐋𝐞𝐜𝐭𝐮𝐫𝐞 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 Kathrin shared four critical success factors in drug development: 𝐈𝐧𝐭𝐞𝐫𝐚𝐜𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐚𝐮𝐭𝐡𝐨𝐫𝐢𝐭𝐢𝐞𝐬: Get their advice early to create data that will bring you forward. 𝐑𝐢𝐠𝐡𝐭 𝐬𝐞𝐭𝐮𝐩 𝐨𝐟 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐩𝐥𝐚𝐧𝐬: Ensure relevant endpoints, patient groups, and fit-for-purpose design to demonstrate safety and efficacy. 𝐑𝐢𝐠𝐡𝐭 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬/𝐩𝐞𝐨𝐩𝐥𝐞: Collaborate with CROs, CDMOs, regulatory consultants, QM systems, and skilled professionals to meet standards accepted by regulatory authorities. 𝐌𝐨𝐧𝐞𝐲: Adequate funding is essential to finance the development steps from early pre-clinical to clinical stage and successful market authorisation. Thank you for organizing and inviting Kathrin! Christin Menke REACH University of Münster FH Münster  Kim N. Kirchhoff Worldfactory Start-up Center (WSC) Hanna Zimmermann Gateway Gateway Excellence Start-up Center University of Cologne Shanika Yadav KOALA Startup Network Julia P. RWTH Innovation Centrum für Entrepreneurship & Transfer garage33 Are you an inventor with an innovative approach to develop novel treatments in therapeutic areas with a high unmet need? Connect with Kathrin to explore how we can help bring your innovation to life! #NLC #bringsciencetolife

27

EvlaBio AG is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity. Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy. We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design. Meet EvlaBio @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

4

➡️ Unlock the secrets to successful R&D in Switzerland! The Basel Area has long been recognized as a hub for innovation, and now we’re making it even easier to navigate the region's vast potential for research and development. Did you know? ✅ The Basel Area is home to 700+ life sciences companies ✅ 16 world-class universities and research institutes and over 1,000 research groups have set foot in the region ✅ Over 33,000 people in the area are employed in life sciences, accounting for 7% of total regional employment, which is higher than any other region in the world. With its unique blend of world-class research institutions, a thriving startup scene, and tailored support for businesses of all sizes, the Basel Area is your gateway to groundbreaking innovation in life sciences, tech and beyond. Discover what’s inside the handbook: 🔍 Regional R&D opportunities 🔍 Innovation infrastructure and resources 🔍 Guidance on forming strategic partnerships with academia and industry 📥 Download it here: https://lnkd.in/evxcXyvS ---- Follow us on #discoverthebaselarea Basel Area Business & Innovation #BaselArea #Business #Innovation #Switzerland #LifeSciences #Research #RandD #Biotech #Healthtech #Medtech InvestinSwitzerland | Business Location Switzerland | Fabio Marelli | Annelise Michel | Kirsten Detrick | Shwen Gwee | ¦Daniel Meier | Valentina Francia | Paul Eschmann

84

4 Kommentare

For all of you who can't wait or unfortunately can't attend the ACROConnect workshop at Novartis Campus in Basel, here is a little insight into one of our R&D projects on TCRm, presented by our VP Services & Operations Philipp Kuhn.   Classical antibodies in oncology bind to extracellular targets. The problem is that >80% of the proteome are intracellular proteins and therefore can't be reached by classical antibodies. However, the fact that intracellular proteins are presented as peptides on MHCI complexes and can therefore be recognized by TCRs is a game changer for tumor therapy, ushering in the era of TCRm. TCRm antibodies can precisely recognize this peptide-MHCI complex. The tricky part is to bind only the tumor-specific peptides and avoid off-target effects. Using our naïve human antibody library, we have developed TCRm antibodies that recognize the Wilms tumor antigen WT1 but not the negative control, and outperform reference antibodies in several aspects. This proof of concept was just a precursor for further TCRm antibodies from our workshop. Stay tuned! #YUMAB #Antibodies #TCRm #ACROBiosystems

27

🧬🍎Are you, or someone you know, a later-stage startup dedicated to innovating the healthcare industry? Are you looking for strategic partnerships to scale your venture in Switzerland, across Europe and beyond? We're looking for you! 🤝 The Kickstart 2024 Program, which focuses on making commercial deals and investments between our partners and ventures like yours happen. Since 2019 we supported startups from 11 countries! 📈 🌍 While global investments in digital health took a toll in 2023 with $13.2 billion raised, median deal size remained at $4M — the highest on record and M&A nearly doubled in Q4’23, indicating encouraging signs of the market picking up.Since the launch of the vertical in 2019, Kickstart’s Health & Wellbeing vertical has supported 39 startups in securing 35 PoCs, with  our cohorts raising a total over $482M in investment. Our alumni include Kaia Health, Huma, VAY, Sidekick Health, OneDoc, Uplyfe.io, TOM Medications, Health Yourself, PIPRA and others. 🚀 This year, the Health & Wellbeing vertical has partnered with leading industry players such as Die Mobiliar, AXA, Sanitas Krankenversicherung, MSD Switzerland, Swisscom Ventures & Stadt Zürich, ready to collaborate on the following opportunities: ✅Lifestyle & Prevention  ✅Care Coordination & Access To Healthcare ✅Corporate Wellbeing ✅Public Health ✅Health & Wealth ✅Health Systems, Process Optimisation & Automation & More… Get an overview of the benefits here 👉 https://lnkd.in/eJkCJ76a Apply until May 11th: https://lnkd.in/e7WRE6Bp Questions? Get in touch with our Health & Wellbeing team Claire-Marine Pandraud and Noémie Délèze or get info here 👉 https://lnkd.in/eENyZBsZ We are excited to receive your applications and/or startup nominations! 🚀💙 #healthcare #innovation #scaleups #venture #digitalhealth #pilot #commercialprojects #marketentry #partnerships #deeptech #tech #collaboration #sustainability #kickstarters24 #makeithappen #SDGs #circulareconomy

48

3 Kommentare

📢 Pentixapharm AG Acquires Target Discovery Business of Glycotope GmbH, effective July 1st.  This strategic acquisition of the Berlin-based biotech company marks a significant milestone in their mission to develop novel targeted radiopharmaceuticals against a broad range of malignancies. 🌟 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻: • 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼: The deal includes a portfolio of 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 against multiple oncology targets, 𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀, cell banks, a 𝘁𝘂𝗺𝗼𝗿 𝘁𝗮𝗿𝗴𝗲𝘁 𝗱𝗮𝘁𝗮𝗯𝗮𝘀𝗲, and essential equipment.    • 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗜𝗻𝘁𝗲𝗹𝗹𝗲𝗰𝘁𝘂𝗮𝗹 𝗣𝗿𝗼𝗽𝗲𝗿𝘁𝘆: This acquisition broadens the 𝗜𝗣 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 beyond the CXCR4 receptor, 𝗱𝗼𝘂𝗯𝗹𝗶𝗻𝗴 the 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 and expanding business and clinical opportunities.    • 𝗘𝘅𝗽𝗲𝗿𝘁 𝗧𝗲𝗮𝗺: Pentixapharm welcomes an 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝘁𝗲𝗮𝗺 𝗼𝗳 𝟰𝟬 seasoned executives, R&D specialists, and administrators from Glycotope.    • 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻: Patrik Kehler, former CSO of Glycotope, will join as Pentixapharm's 𝗖𝗦𝗢, and Henner Kollenberg, former CEO of Glycotope, will become the 𝗖𝗵𝗶𝗲𝗳 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗢𝗳𝗳𝗶𝗰𝗲𝗿.    💬 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗣𝗲𝗻𝘁𝗶𝘅𝗮𝗽𝗵𝗮𝗿𝗺'𝘀 𝗟𝗲𝗮𝗱𝗲𝗿𝘀: “Glycotope’s pipeline comprises 𝘀𝗲𝘃𝗲𝗿𝗮𝗹 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀 that can be 𝘂𝘀𝗲𝗱 𝗶𝗺𝗺𝗲𝗱𝗶𝗮𝘁𝗲𝗹𝘆 for 𝗽𝗿𝗼𝗼𝗳-𝗼𝗳-𝗰𝗼𝗻𝗰𝗲𝗽𝘁 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 as next generation radiopharmaceuticals,” said Dr. Hakim Bouterfa, CEO of Pentixapharm AG. “We look forward to 𝗺𝗮𝘅𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝘁𝗵𝗲 𝘀𝘆𝗻𝗲𝗿𝗴𝘆 of Pentixapharm’s know-how and Glycotope’s target discovery for the 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 in both diagnostics and therapeutic applications.” “The transaction 𝘀𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝘀 our 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 and administrative capacities, facilitating a 𝘀𝗲𝗮𝗺𝗹𝗲𝘀𝘀 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 to the 𝗙𝗿𝗮𝗻𝗸𝗳𝘂𝗿𝘁 𝗦𝘁𝗼𝗰𝗸 𝗘𝘅𝗰𝗵𝗮𝗻𝗴𝗲,” noted 𝗗𝗿. 𝗔𝗻𝗱𝗿𝗲𝗮𝘀 𝗘𝗰𝗸𝗲𝗿𝘁, Chairman of the Supervisory Board of both Pentixapharm and Eckert & Ziegler SE. This acquisition positions Pentixapharm to develop 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 by leveraging Glycotope’s 𝘂𝗻𝗶𝗾𝘂𝗲 𝗚𝗹𝘆𝗰𝗼𝗧𝗮𝗿𝗴𝗲𝘁𝘀—tumor-associated 𝗰𝗮𝗿𝗯𝗼𝗵𝘆𝗱𝗿𝗮𝘁𝗲 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲𝘀 with 𝘀𝘂𝗽𝗲𝗿𝗶𝗼𝗿 𝘁𝘂𝗺𝗼𝗿-𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰𝗶𝘁𝘆. These advancements have the potential to close the treatment gap for many solid tumors, enhancing both diagnostic and therapeutic applications. 🔗 Learn More: https://lnkd.in/eCXh35Nw #NuclearMedicine #Radiopharmaceuticals #Acquisition #PrecisionMedicine  

106

Switzerland’s Venture Capital Trends in 2024 In 2023 Switzerland was one of the top 5 European countries for Venture Capital Investments with fintech, biotech and medtech companies raising over $2.3 billion dollars. But what's the outlook for the future? The total capital raised in the Venture Capital market in Switzerland is projected to reach €651.2m in 2024. Here is what has been happening behind the scenes: 📌The cantons of Zurich, Vaud and Zug had the most notable VC investments in the past year 📌There is a high number of active VC funds with 52 funds engaging in fundraising activities 📌Mid-sized investments decreased by CHF 10-20 million 📌Early-stage investments remained relatively stable 📌Foreign investment projects in Switzerland went up by 50% to about 89 projects even as Europe faced a 4% decline. 📌Venture capital invested in the first two quarters of the year fell by 9.5% to CHF1.1 billion compared to 2023. VC investment trends show a need for strategic diversification, scaling support, and international collaboration to sustain the growth and success of Swiss start-ups in the global market. Get in touch with SigTax to explore opportunities across the Swiss startup landscape. #VentureCapital #Switzerland2024 #SwissStartups #VCInvestments #Fintech #Biotech #Medtech #SIGTAX

9

The Swiss Venture Capital Report's half year update makes for interesting reading 🗞 Biotech performed well and with surveyed investors reporting ‘dry powder’; i.e. funds available for investment, we hope this trend is set to continue. iOnctura's Series B of 76.5M CHF was the second largest of the period 👏 👉 Read the full report here: https://lnkd.in/eYpAudxe

18

🌟 Exciting News from Ikerian! 🌟 We are thrilled to announce the successful first close of our Series B funding round, with a substantial $8 million raised! A warm welcome to our new investor, Sanoptis, and a heartfelt thank you to our returning supporters THINC Ventures, Zürcher Kantonalbank, and Verve Ventures. Your continued trust and support mean the world to us. This funding is not just financial; it’s a step forward in our journey. In partnership with Sanoptis, we're set to enhance our RetinAI Discovery platform, leveraging the power of AI 🤖 and machine learning to transform data management in healthcare. Our goal? To provide cutting-edge tools that offer real-world evidence insights and streamline data workflows, ultimately improving patient outcomes across Europe. But that's not all! These advancements will allow us to delve deeper into research, enhance our technologies, and expand our reach, ensuring that healthcare providers and researchers have access to the crucial data they need to make informed decisions. 👉 We invite you to join us on this journey. What impacts do you think AI will have on healthcare in the coming years? Share your thoughts, and let’s discuss the bright future ahead! 👍 Like, 💬 Comment, and 🔗 Share to spread the word about how AI and machine learning are revolutionizing healthcare analytics. #HealthTech #ArtificialIntelligence #MachineLearning #DataManagement #Innovation #FundingNews #Ikerian

2

How has Swiss biotech been performing in 2023? 📈 In April the Swiss Biotech Report 2024 was released and its findings were very encouraging for Switzerland's biotech landscape. 2023 marked a 50% increase in capital investment compared to 2022 and reached $2.2 billion. The industry also achieved a revenue of $8 billion in Switzerland. 💸 With public and private companies raising significant funds and Swiss contributions to the cautious yet optimistic IPO market, the country remains a leader in the industry. 🏅 Find out more in the article! ⬇️ https://lnkd.in/devcxekD #swissbiotech #SwissBiotechReport #capitalinvestment #revenuegrowth #IPO #biotechindustry #innovation #healthcare #Switzerland #biotechnews #pharma NewBiologix | Noema Pharma | Alentis Therapeutics | Rejuveron Life Sciences AG | MoonLake Immunotherapeutics (NASDAQ: MLTX) | Lonza | Oculis | CRISPR Therapeutics | Vertex Pharmaceuticals | Novartis | Roche | Flatiron Health | University of Pennsylvania

26

Join this interesting discussion on “Investments into global HC systems” at the #swissbiotechday2024 today (22nd April) at 17:30 in the “Sydney” room at the Congress Center, Basel.   Our CEO, Sitara Merchant, will share her thoughts on the importance of #HCinvestments in bridging #healthprotectiongap especially in the #LICs and #MICs, role of #inclusivefinance in expanding access to #healthcare and how relevant stakeholders can complement each other’s work to maximise the impact and help build #resilientcommunities.   More info here 👉 https://lnkd.in/d9R-bHyj   #swissbiotechday #biotechnology #healthcareinvestment #healthfinancing #financialinclusion #healthequity

5

Pilatus Biosciences, a US/Swiss -based R&D startup originating from the Ludwig Institute for Cancer Research (Lausanne), stands on the cutting-edge of developing First-in-Class Biologics, focusing on metabolic checkpoints. Our pioneering approach, backed by the Cancer Research Institute (New York), targeting Immunometabolism triggers immune microenvironment reprogramming to combat cancer. Meet Pilatus Biosciences SA @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

2

1 Kommentar